Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

KARMA

Financiado

From the understanding of KRAS RAF membrane dynamics to new therapeutic strategi...

From the understanding of KRAS RAF membrane dynamics to new therapeutic strategies in cancer Cellular homeostasis is controlled by the RAS-MAPK pathway. This pathway is dysregulated in human diseases, especially cancer, in which more than 50% of cases carry aberrations that hyperactivate RAS-MAPK signaling. In this contex... ver más

31/07/2026

UNITO

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI TORINO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-02-01

ERC-2020-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 4 años

0% 100% 100%

2 Participantes

UNITO

2.00M€ | Lider

HERLUSA

314.90K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-116824RB-I00 CARACTERIZACION DE LA FUNCION Y POTENCIAL TERAPEUTICO DE LOS... 278K€ Cerrado

PID2019-105483RB-I00 NUEVAS INTERACCIONES DE KRAS RELEVANTES PARA SU ACTIVIDAD ON... 182K€ Cerrado

SAF2013-42742-R NUEVAS ESTRATEGIAS PARA INHIBIR K-RAS ONCOGENICO Y ANALISIS... 242K€ Cerrado

BFU2017-87244-P INTERPRETACION TRANSCRIPCIONAL DE SEÑALES RTK 230K€ Cerrado

CNS2023-143636 Cáncer 190K€ Cerrado

UB-RASDisease The ubiquitin system in RAS driven disease 2M€ Cerrado

Duración del proyecto: 65 meses Fecha Inicio: 2021-02-01
Fecha Fin: 2026-07-31

Líder del proyecto

UNIVERSITA DEGLI STUDI DI TORINO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Cellular homeostasis is controlled by the RAS-MAPK pathway. This pathway is dysregulated in human diseases, especially cancer, in which more than 50% of cases carry aberrations that hyperactivate RAS-MAPK signaling. In this context, KRAS mutations are the most frequent oncogenic drivers. Therapeutic suppression of pathogenic KRAS-RAF-MAPK signaling to achieve disease control in cancer patients still represents a challenging target. KRAS dimers and multimers at the membrane (collectively referred, together with adaptors and effectors, as to KRAS signalosome) influence the activation of KRAS signaling. I provided the first biological evidence that dimerization is required for the function of oncogenic KRAS (Ambrogio et al, Cell, 2018). Indeed, one fascinating and still largely unexplored aspect of KRAS biology is the functional impact of KRAS complexes at the membrane for signaling and drug sensitivity. No inhibitors of oncogenic KRAS clustering have been identified so far. Interestingly, wild-type KRAS antagonizes oncogenic KRAS, resulting in reduced oncogenic signaling. The overarching goal of this proposal is the characterization in vitro and in vivo of the KRAS signalosome in terms of functional dynamics and related actionable vulnerabilities. My strong background in KRAS biology provides me with the expertise to propose an ambitious, yet feasible plan to understand the tumor suppressor effect of wild-type KRAS protomers in mutant KRAS-driven complexes by identifying and validating membrane interactors differentially recruited by wild-type and mutant KRAS (Work package 1). In parallel, I will study the relevance of RAF kinases localization at the membrane as key feature to sustain oncogenic MAPK activity in vivo (Work package 2). Finally, I will screen new compounds to interfere with RAFs function at the cell membrane and will determine the therapeutic impact of disrupting mutant KRAS signalosome using mouse models in vivo (Work package 3).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores